BRight DCB First-in-Human Study

  • End date
    Oct 26, 2022
  • participants needed
  • sponsor
    Biotronik CRC Inc.
Updated on 26 September 2021


The primary aim of this clinical study is to assess the safety and clinical performance of the BRight drug-coated balloon (DCB) in the treatment of lower limb arteries stenosis in subjects with Peripheral Artery Disease (PAD).

The primary endpoint will be Late Lumen Loss (LLL) of the target lesion at 6 months.

Condition peripheral arterial disease, peripheral arterial diseases, Peripheral Arterial Disease (PAD), peripheral artery disease
Treatment BRight DCB
Clinical Study IdentifierNCT04525794
SponsorBiotronik CRC Inc.
Last Modified on26 September 2021


Yes No Not Sure

Inclusion Criteria

The subject has provided written informed consent
The subject is willing to participate in the clinical investigation and to comply with the study procedures and follow-up visits
Lifestyle-limiting claudication or rest pain requiring treatment of superficial femoral (SFA) and/or proximal popliteal artery (PPA)
Rutherford-Becker Clinical Category of 2, 3 or 4
Target vessel reference diameter 5 mm and 6 mm (by visual estimation)
De novo lesion with >50% stenosis by operator visual estimate within the SFA and/or proximal popliteal arteries in a single limb
Lesion must be located 1 cm below the Common Femoral Artery (CFA) bifurcation and terminate distally at 3 cm proximal to the knee joint (radiographic joint space)
Single lesion length 100 mm for de novo stenotic lesions, or 70 mm for occluded lesions (one long lesion or multiple serial lesions) by operator visual estimate. Note: Only 1 lesion per patient can be treated. Multiple serial lesions are allowed provided that they can be treated as a single lesion with one balloon
Successful guidewire crossing of lesion
After pre-dilatation, the target lesion is 30% residual stenosis with no flow limiting dissection and treatable with a single balloon
Inflow artery is patent, free from significant lesion stenosis (>50% stenosis considered significant) as confirmed by angiography
Target limb with at least 1 patent (less than 50% stenosis) tibio-peroneal run-off vessel in the target limb confirmed at baseline. (Note: treatment of outflow disease is not permitted.)

Exclusion Criteria

Females who are pregnant, lactating, or intended to become pregnant, or males intending to father children during the study
Subject under current medication known to affect CYP3A4 metabolism
Contraindication to dual anti-platelet therapy
Subject is receiving chronic anticoagulation therapy (e.g. low molecular weight heparin, warfarin, or novel direct oral anticoagulants (N(D)OACs))
Known intolerance to study medications, Limus- like drug or contrast agents that in the opinion of the investigator could not be adequately pretreated
Current participation in an investigational drug or another device study
History of hemorrhagic stroke within 3 months
Patients with a history of Myocardial Infarction (MI) or thrombolysis within 30 days prior-index procedure
Previous or planned surgical or interventional procedure within 14 days before or 30 days after index procedure (successful treatment of the ipsilateral and contralateral iliac arteries is permitted prior to enrollment- contralateral iliac artery treatment with no drug eluting technology is allowed during the index procedure)
Prior endovascular treatment of the target lesion (e.g., POBA, DCB, BMS, DES, cutting balloons, scoring balloons, cryoplasty, thrombectomy, atherectomy, brachytherapy or laser devices)
Previous placement of a bypass graft proximal to the target lesion
Chronic renal insufficiency (eGFR < 30 mL/min within 72 hours prior to index procedure)
No normal proximal arterial segment in which duplex ultrasound velocity ratios could be measured
Subject is unable to walk without assistance (e.g. walker, cane)
Subject is receiving immunosuppressant therapy
Subject has known or suspected active infection at the time of the index procedure
Subject has platelet count < 100,000/mm3 or > 700,000/mm3
Subject has white blood cell (WBC) count < 3,000/mm3
Subject is unable to tolerate blood transfusions because of religious beliefs or other reasons
Subject has history of gastrointestinal hemorrhage requiring a transfusion within 3 months prior to the index procedure
Life expectancy less than 12 months due to other comorbidities, that in the investigators opinion, could limit subject ability to comply with the study required follow-up visits/procedure and threaten the study scientific integrity
Treatment of the contralateral limb during the same procedure or within 30 days following the study procedure (exclusive of the iliac arteries, which can be treated prior to enrollment or during the index procedure if no drug eluting technology is used)
Non femoral vascular access
Target lesion would require treatment with more than one balloon
Known inadequate distal outflow
Acute or sub-acute thrombus in the target vessel
Aneurysmal target vessel
Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, brachytherapy) during the study procedure in the target lesion or target vessel
Presence of concentric calcification that precludes PTA pre-dilatation
Significant contralateral or ipsilateral common femoral disease that requires intervention during the index procedure
Persistent hemodynamically-significant stenosis following predilatation or residual stenosis of >30%, stent placement, or flow-limiting (Grade D or greater) dissection following pre-dilatation
In-stent restenosis
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note